Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8416 to 8430 of 8900 results

  1. Diabetes: annual HbA1c (children) (IND49)

    This indicator has been updated and replaced by NICE indicator 298 and NICE indicator 299.

    Withdrawn indicator

  2. Diabetes: annual care processes (children) (IND48)

    This indicator has been updated and replaced by NICE indicator 296 and NICE indicator 297.

    Withdrawn indicator

  3. Cardiovascular disease prevention: cholesterol treatment target (secondary prevention) (IND268)

    This indicator has been updated and replaced by NICE indicator 278.

    Withdrawn indicator

  4. Kidney conditions: CKD and SGLT2 inhibitors (IND262)

    This indicator has been updated and replaced by NICE indicator 322.

    Withdrawn indicator

  5. Multiple long-term conditions: falls prevention advice (IND209)

    This indicator has been removed following the publication of NICE guideline NG249.

    Withdrawn indicator

  6. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  7. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  8. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Withdrawn guidance

  9. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

    Withdrawn guidance

  10. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  11. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  12. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  13. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  14. The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence (TA56)

    This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)] 

    Withdrawn guidance

  15. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

    This guidance has been updated and replaced by NICE technology appraisal guidance 898.

    Withdrawn guidance